-
-
-
-
-
-
-
Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
-
-
-
-
-
-
-
Revance Therapeutics' (RVNC) Remains on Track to Submit Daxi BLA in 1H22 and get New PDUFA in 2H22 - Needham
-
-
-
-
-
-
-
Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia
-
-
-
-
-
-
-
Revance Reports Second Quarter 2020 Financial Results, Provides Corporate Update
-
-
-
-
-
-
-
Revance Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update
-
-
-
-
15,418 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

